According to a previous report suggesting CD3+CD56+ NKT cells to be used for CLL therapy after in vitro augmentation [36], it will be important to evaluate TCR-Vβ-specific CD3+CD161+ cells for that purpose. The gene discussed is NCAM1; the disease is B-cell chronic lymphocytic leukemia.